The effect of targeted delivery of anti-TNF-α oligonucleotide into CD169+ macrophages on disease progression in lupus-prone MRL/lpr mice

Biomaterials

Volumn 33, Issue 30, 2012, Pages 7605-7612

  Huang, Zhen ^a   Zhang, Zhengping ^a   Zha, Yinhe ^a   Liu, Jialin ^a   Jiang, Yucui ^a   Yang, Yang ^a   Shao, Juan ^a   Sun, Xulun ^a   Cai, Xin ^a   Yin, Yuan ^a   Chen, Jiangning ^a   Dong, Lei ^a   Zhang, Junfeng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antisense oligonucleotide; CD169+ macrophage; Drug delivery; Systemic lupus erythematosus; TNF

Indexed keywords

AGAROSE; ANTISENSE OLIGONUCLEOTIDES; AUTOIMMUNE DISORDER; CELLULAR LOCALIZATION; DISEASE PROGRESSION; NUCLEIC ACID DRUGS; SOLUBLE RECEPTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGETED DELIVERY; THERAPEUTIC EFFECTS; TISSUE DISTRIBUTIONS;

DRUG DELIVERY; MAMMALS; MONOCLONAL ANTIBODIES; NUCLEIC ACIDS; OLIGONUCLEOTIDES;

MACROPHAGES;

AGAROSE; ANTISENSE OLIGONUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD169+ MACROPHAGE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG TISSUE LEVEL; FEMALE; HOMEOSTASIS; HYDROGEL; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE DISTRIBUTION;

ANIMALS; CELL PROLIFERATION; DISEASE PROGRESSION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; IMPLANTS, EXPERIMENTAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPH NODES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; OLIGONUCLEOTIDES, ANTISENSE; SEPHAROSE; SIALIC ACID BINDING IG-LIKE LECTIN 1; SPLEEN; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS;

EID: 84864967595     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.074     Document Type: Article

References (33)

1. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994, 180:1961-1966.
2. Strom T.B., Koulmanda M. Cytokine related therapies for autoimmune disease. Curr Opin Immunol 2008, 20:676-681.
3. Tsiodras S., Samonis G., Boumpas D.T., Kontoyiannis D.P. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83:181-194.
4. Prud'homme G.J., Lawson B.R., Theofilopoulos A.N. Anticytokine gene therapy of autoimmune diseases. Expert Opin Biol Ther 2001, 1:359-373.
5. Verma I.M. Gene therapy: the need for basic science. Mol Ther 2000, 2:531.
6. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
7. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
8. Shi X., Xie C., Kreska D., Richardson J.A., Mohan C. Genetic dissection of SLE: SLE1 and FAS impact alternate pathways leading to lymphoproliferative autoimmunity. J Exp Med 2002, 196:281-292.
9. Enzler T., Bonizzi G., Silverman G.J., Otero D.C., Widhopf G.F., Anzelon-Mills A., et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006, 25:403-415.
10. Dong L., Xia S., Chen H., Chen J., Zhang J. Spleen-specific suppression of TNF-alpha by cationic hydrogel-delivered antisense nucleotides for the prevention of arthritis in animal models. Biomaterials 2009, 30:4416-4426.
11. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994, 174:83-93.
12. Frese-Schaper M., Zbaeren J., Gugger M., Monestier M., Frese S. Reversal of established lupus nephritis and prolonged survival of New Zealand black × New Zealand white mice treated with the topoisomerase I inhibitor irinotecan. J Immunol 2010, 184:2175-2182.
13. Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
14. ten Hagen T.L., van Vianen W., Bakker-Woudenberg I.A. Isolation and characterization of murine Kupffer cells and splenic macrophages. J Immunol Methods 1996, 193:81-91.
15. Aringer M., Smolen J.S. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008, 10:202.
16. Aringer M., Graninger W.B., Steiner G., Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004, 50:3161-3169.
17. Aringer M., Houssiau F., Gordon C., Graninger W.B., Voll R.E., Rath E., et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009, 48:1451-1454.
18. Yokoyama H., Kreft B., Kelley V.R. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995, 47:122-130.
19. Kim N., Ussin L., Cheng X., Murali R., Sullivan K.E. TNFalpha inhibition in MRL/lpr mice ameliorates pulmonary but not renal disease. J Autoimmun 2002, 19:215-222.
20. Postal M., Appenzeller S. The role of Tumor Necrosis Factor-alpha (TNF-alpha) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011, 56:537-543.
21. Apostolaki M., Armaka M., Victoratos P., Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 2010, 11:1-26.
22. Zhu L.J., Yang X., Yu X.Q. Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol 2010, 2010:465898.
23. Mebius R.E., Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005, 5:606-616.
24. Barral P., Polzella P., Bruckbauer A., van Rooijen N., Besra G.S., Cerundolo V., et al. CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 2010, 11:303-312.
25. Martinez-Pomares L., Gordon S. CD169+ macrophages at the crossroads of antigen presentation. Trends Immunol 2012, 33:66-70.
26. Rosas-Ballina M., Ochani M., Parrish W.R., Ochani K., Harris Y.T., Huston J.M., et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A 2008, 105:11008-11013.
27. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2:764-766.
28. Shlomchik M.J., Madaio M.P., Ni D., Trounstein M., Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994, 180:1295-1306.
29. Sfikakis P.P., Boletis J.N., Tsokos G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005, 17:550-557.
30. Fujii T., Okada M., Mimori T., Craft J. The transmembrane form of TNF-alpha drives autoantibody production in the absence of CD154: studies using MRL/Mp-Fas(lpr) mice. Clin Exp Immunol 2002, 130:224-232.
31. Rose L.M., Latchman D.S., Isenberg D.A. Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Br J Rheumatol 1997, 36:158-163.
32. Crispin J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008, 181:8761-8766.
33. Chatzidakis I., Mamalaki C. T cells as sources and targets of TNF: implications for immunity and autoimmunity. Curr Dir Autoimmun 2010, 11:105-118.